Failed clinical trials may be routine in the pharma world, but one such event has had a broad impact in Japan this week, amplified by recent meteoric rises in the product developer's stock and positive local sentiment around cell-based therapies.
An announcement by Tokyo-based venture SanBio Co. Ltd. that its regenerative medicine SB623 missed the primary efficacy endpoint in...







